Pipeline
Genentech reports phase 4 Vabysmo data among underrepresented DME patients
Study is referred to as the first retinal trial to focus on this patient demographic, finding similar average vision gains to prior research.
Research
Vabysmo provides long-term durability in DME extension study
Four-year data finds nearly 80% of patients extended treatment intervals to 3 or 4 months, with 90% reporting absence of DME.
Products
Genentech's Vabysmo PFS earns FDA approval for retinal diseases
Prefilled Syringe version of the bispecific antibody is indicated for treating wet AMD, DME, and RVO.
Pipeline
Genentech releases 72-week data on VABYSMO for RVO
Long-term results indicate a positive safety profile for the therapy’s third potential indication.Products
FDA approves Vabysmo for RVO
Approval marks the third indication for Genentech’s faricimab-svoa formulation.Products
Positive long-term data reported in phase 3 trials of Vabysmo for RVO
Treatment has the potential to be the third indication for the FDA-approved drug, joining wet AMD and DME.
Pipeline
FDA accepts sBLA for Vabysmo to treat RVO
If approved, Vabysmo would become the first bispecific antibody available for blinding retinal conditions.
Research
Genentech reports Vabysmo superiority for retinal drying versus aflibercept for wet AMD, DME
Post hoc analysis supports use of Vabysmo for better blood vessel stability in the macula.
Pipeline
Genentech reports positive data in phase 3 trials of Vabysmo for RVO
BALATON and COMINO studies both achieved primary endpoints.
Archives